Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Stem cells slow motor neurone disease in rats

16 October 2006

By Dr Jess Buxton

Appeared in BioNews 380

US researchers have used human stem cells to lessen the symptoms of motor neurone disease in rats bred to have symptoms of the condition. The scientists, based at Johns Hopkins University, Baltimore, showed that injecting fetal nerve stem cells into the spines of rats with amytrophic lateral sclerosis (ALS) delays nerve damage and slightly prolongs the life of the animals. Team leader Vassilis Koliatsos says the study, published in the journal Transplantation, offers 'proof of principle' for using stem cell transplants to treat the disease.

ALS, also known as Lou Gehrig's disease, is a progressive, incurable paralysis caused by gradual damage to motor neurons - nerve cells in the brain and spine. As the nerves gradually waste away, people with the condition eventually lose all control over their voluntary movements. The causes of motor neurone disease remain largely unknown, although ten per cent of cases are linked to an altered gene, called SOD-1. In the latest study, the researchers used genetically altered rats that have a mutated human SOD-1 gene, which means they develop symptoms of ALS.

The scientists injected fetal nerve stem cells into the lower spine of presymptomatic rats, and dead stem cells in the spines of control animals. Both groups of rats were then weighed and tested for strength twice a week for 15 weeks. According to Koliatsos, weight loss indicates the onset of the disease, while measuring strength shows how quickly it is progressing. The scientists determined how strong the rats were by coaxing them to crawl up an angled plank, and measuring the angle at which they could no longer cling on for more than five seconds.

The team found that the treated animals started losing weight at 59 days and lived for 86 days after the injection, while the control group started losing weight at 52 days and lived for 75 days. Microscopic examination of the transplanted cells revealed that more than 70 per cent of them developed into nerve cells, and many formed new connections to other cells in the rats' spinal cords. The transplanted cells also made proteins specific to nerve cells, such as a growth factor called GNDF.

Koliastsos cautions that although clinical applications are still 'far from possible', the fact that the cell transplants formed new nerve cells in the spinal cord was 'a pleasant surprise'. 'We were extremely surprised to see that the grafted stem cells were not negatively affected by the degenerating cells around them, as many feared introducing healthy cells into a diseased environment would only kill them', he said.
The team now plans to carry out further experiments in which stem cells will be injected along the full length of the spine, so that nerves and muscles above the waist - especially those involved in breathing - also benefit. They hope this will further increase the lifespan of the affected animals.


Dr Jess Buxton is Contributing Editor at BioNews and a Trustee at the charity that publishes it, the Progress Educational Trust (PET). She is co-author of The Rough Guide to Genes and Cloning (buy this book from Amazon UK) and Human Fertilisation and Embryology: Reproducing Regulation (buy this book from Amazon UK).

SOURCES & REFERENCES
Medical News Today | 16 October 2006
 
The Independent | 16 October 2006
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

28 May 2012 - by Dr Lux Fatimathas 
A chemical produced by stem cells promotes recovery in mice with the autoimmune neurological disease, multiple sclerosis. Hepatocyte growth factor, which is produced by human mesenchymal stem cells, appeared to both repair existing damage and prevent future neurological harm in a mouse model of the disease...
02 April 2012 - by Dr Linda Wijlaars 
A clinical trial to test the safety of a stem cell treatment for amyotrophic lateral sclerosis, the most common form of motor neurone disease, suggests that the new therapy is safe and well-tolerated. Encouragingly, one of the 12 patients participating in the study showed some improvement, although the trial was not designed to test the treatment's efficacy...
28 November 2011 - by Dr Marianne Kennedy 
On 18 November, Richard Grosjean became the first patient to receive a pioneering stem cell treatment in the upper part of the spinal cord. His procedure is part of an ongoing US-based clinical trial aimed at assessing the safety of injecting neural stem cells taken from eight-week-old fetuses into the spinal cords of patients with amyotrophic lateral sclerosis (ALS)...
26 September 2011 - by George Frodsham 
Researchers have identified a strong link between a genetic fault and two common neurological disorders. Two independent studies have found that the mutation is common in patients with amyotrophic lateral sclerosis (ALS) and patients with frontotemporal dementia (FTD), particularly if the disease is familial...
01 June 2010 - by Victoria Kay 
A new research project, which will use human stem cells to artificially create the diseased brain cells affected in Motor Neurone Disease (MND) could pave the way for a cure for sufferers....

03 February 2005 - by BioNews 
US researchers have managed to grow motor neurons, using human embryonic stem (ES) cells, in the laboratory for the first time. The scientists, based at the University of Wisconsin, say their achievement could help research into motor neurone disease. It may eventually be possible to treat the condition using transplants...
28 September 2004 - by BioNews 
Professor Ian Wilmut, the scientist who lead the team that cloned Dolly the sheep, has applied for a licence to clone human embryos. He and his team, based at the Roslin Institute outside of Edinburgh, hope to use the cloned embryos in the study of, and to work towards a...
23 February 2004 - by BioNews 
Scientists at the Roslin Institute in Scotland, who cloned Dolly the sheep, have confirmed their intention to apply for a license to derive cloned human embryo stem cells. Writing in New Scientist magazine last week, team leader Ian Wilmut says that he wants to clone cells from a patient with...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation